Tag: Nasdaq:CCCC
C4 Therapeutics Announces Pricing of Public Offering
WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new...
C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader...
– CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across a Panel of Multiple Myeloma Cell Lines Including...